Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17985228 | 1.00 | GRM2 (0.53) | GRM2IDO1SCDS1PR5SYK | |
| SCHEMBL17985192 | 0.89 | GRM2 (0.51) | GRM2IDO1SCDSYKSLC6A3 | |
| SCHEMBL17985193 | 0.89 | GRM2 (0.51) | GRM2IDO1SCDSYKSLC6A3 | |
| SCHEMBL16591225 | 0.82 | GRM2 (0.50) | GRM2IDO1SCDSYKCYP2C9 | |
| SCHEMBL17985198 | 0.82 | GRM2 (0.50) | GRM2IDO1SCDSYKCYP2C9 | |
| SCHEMBL17985220 | 0.78 | GRM2 (0.52) | GRM2IDO1SLC6A4 | |
| SCHEMBL16585444 | 0.78 | GRM2 (0.52) | GRM2IDO1SLC6A4 | |
| SCHEMBL8705390 | 0.75 | S1PR5 (0.40) | GRM2IDO1S1PR5SLC6A4 | |
| SCHEMBL8705388 | 0.75 | S1PR5 (0.40) | GRM2IDO1S1PR5SLC6A4 | |
| SCHEMBL746825 | 0.73 | GRM2 (0.51) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | GRM2, GRIK2, GRIA2 | GRM2 1/4885IDO1 3195/4885SCD 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.